We enrolled 95 pts. in an investigator blinded, randomized 1:1 trial of MER vs. CEF in PM. Fifty two (55%) had received antibiotics. Seventy (83%) had CSF isolates: 59 (75%) H. influenzae (H. Flu) type B, 11 (14%) S. pneumoniae (S. pneumo), PEN sensitive and 9(11%) N. meningitides (N.mening). Another pt's CSF was (+) for H. flu by (latex agglutination only). Twenty four (25%) had (+) blood cultures also. MER inhibited all H. flu at. 12 γ /ml, all N. mening at.011γ/ ml, all S. pneumo at 0.24 γ/ml. Pts. (3 mos to 12 yrs) got MER (40 mg/kg IV q 8 hrs) or CEF (45 mg/kg IV q 6 hrs). At admission 27 (28%) had seizures and 75 (79%) had Hgb. ≤ 10 gm/dl; they had been ill for a mean of 3.5 dys. (P=NS between groups). MER CSF level (1.4 γ/ml) 30 min after a dose was ≥ 12 × the MIC 100 for H. flu and N. mening and 6 × the MIC 100 for S. pneumo. There was one death (2%) in each group wi. 24 hrs. of Rx. There were no significant differences in outcome for MER vs CEF in BAER > 50:9(21%) vs 6(16%) P=NS, and severe psychometrics, 10(22%) vs 6(14%) P=NS at end of Rx; at 5-7 wk follow up BAER > 50, 8(28%) vs 6(19%) and psychometrics 5(16%) vs 4(13%), P=NS. Thus far 63 pts. have completed a 5-7 mo follow up, and both treatments were similarly effective. MER compared favorably to CEF in PM.
Supported in part by a grant from Zeneca.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Feris, J., Rodriguez, W., Puig, J. et al. Meropenem (MER) vs Cefotaxime (CEF) Therapy (Rx) for Pediatric Meningitis(PM), Therapeutic, and Epidemiologic Observations. • 700. Pediatr Res 41 (Suppl 4), 119 (1997). https://doi.org/10.1203/00006450-199704001-00720
Issue Date:
DOI: https://doi.org/10.1203/00006450-199704001-00720